Targeted Regulatory Probe

The most likely outcome is a focused review by U.S. health agencies rather than a market-wide healthcare shock. FDA, NIH, BARDA, or congressional staff request records on what was known about primate lung damage before human testing proceeded.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.